Save up to $150 - Purchase by Aug 22
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Access TIDES & RNA Insights Anytime, Anywhere
Book Now and Start Streaming TodayPeptides - R&Dkeyboard_arrow_right
Search keyboard_arrow_right
keyboard_arrow_left Hide
Peptides - R&D
search
Peptides - R&D
search
Peptides - R&D 00:00 - 00:30
Cell Penetrating Properties of Cyclotides and Their Applications for Intracellular Targets
- David Craik, PhD - Professor of Biomolecular Structure, University of Queensland
Peptides - R&D 00:30 - 01:00
The Infinite Loop: ML for Discovery, Delivery, and Rapid Manufacturing of Potential Medicines
- Bradley Pentelute, PhD - Professor, Chemistry, Massachusetts Institute of Technology
Peptides - R&D 01:00 - 01:30
Progress in the Development of Targeted Peptide Radiopharmaceuticals: Challenges, Successes and Case Studies
- Jens Kaufmann, PhD - Director Technical Operations, 3B Pharmaceuticals
Peptides - R&D 01:30 - 02:00
Bicycle® Radionuclide Conjugates for Radioisotope Delivery to Solid Tumors
- Anusha Regupathy - Senior Scientist, Medicinal Chemistry, Bicycle Therapeutics
Peptides - R&D 02:00 - 02:30
Translational Development of a Somatostatin Analog for Intraoperative Imaging in Neuroendocrine Tumors
- Ali Azhdarinia, PhD - Associate Professor, IMM-Center for Translational Cancer Research, UT Health Houston
Peptides - R&D 02:30 - 03:00
Peptide-lipid Interplay: Unravelling How Bioactive Peptides Permeate Cell Membranes
- Sonia Henriques - Associate Professor in Biochemistry, The University of Queensland
Peptides - R&D 03:00 - 03:30
A Platform for the Intracellular Generation and High-throughput Screening of Cyclic Peptide Libraries
- Ali Tavassoli, Ph.D. - CSO, Curve Therapeutics, University of Southampton
Peptides - R&D 03:30 - 04:00
Engineering Approaches for Improving Stability and Potency of Peptide-based Drug Leads
- Nicole Lawrence, PhD - Senior Research Fellow, Institute for Molecular Bioscience and Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland
Peptides - R&D 04:00 - 04:30
Synthetic Peptide Enantiomeric Purity Analysis by Chiral HPLC-MS
- Laura Muehlbauer, PhD - Advisor, Eli Lilly and Company
Peptides - R&D 04:30 - 05:00
Bioproduction Platform to Generate Functionalized Disulfide-constrained Peptide Analogues
- Sunhee Hwang, PhD - Scientist 4, Genentech
Peptides - R&D 05:00 - 05:30
CMC of Helicons™ - Helically Constrained Cell Permeable Peptides
- Christopher Martin, PhD - Vice President of Manufacturing, Parabilis Medicines
Peptides - R&D 05:30 - 06:00
BIONDD™ [BEYOND] – Oral Delivery of Biologics with Bioavailability Similar to Subcutaneous Administration
- Karsten Lindhardt, MSc, PhD, DBE - CEO, Biograil
Peptides - R&D 06:00 - 06:30
Refractive Index as an end to end PAT tool for monitoring solid phase synthesis of peptides and oligonucleotides
- John Lopez, PhD - Associate Director Science & Technology, Novartis
Peptides - R&D 06:30 - 07:00
An Inline Monitoring Method Integrated Flow Chemistry for Peptide Synthesis and Manufacturing
- Pengyu Xu, PhD - President and Representative Director, SynCrest Inc.
Peptides - R&D 07:00 - 07:30
Revolutionizing Healthcare: Pioneering Peptide Innovations by AI Computational Design
- Kerry Blanchard, MD, PhD - CEO, Chairman and Founder, Perpetual Medicines
Peptides - R&D 07:30 - 08:00
First De-novo Designed Cyclic Peptides for SORT1 and CNS Delivery
- Lucas Siow - CEO and Co-Founder, ProteinQure
Peptides - R&D 08:00 - 08:30
Program Update on Icotrokinra (JNJ-2113) in Psoriasis: The First-in-Class Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor
- Steven Fakharzadeh, MD, PhD - Global Medical Affairs Leader Immunodermatology, Johnson & Johnson
Peptides - R&D 08:30 - 09:00
Nitto Bispecific siRNA Targeting YAP1/WWTR1 As A Novel Therapeutic Agent for Liver Fibrosis
- Masayuki Sugimoto, PhD - Manager, Nitto Denko Corporation
Peptides - R&D 09:00 - 09:30
Combining Advanced Peptide Screening Methods to Identify Macrocyclic Peptide Candidates for Radiotherapy Development
- Weiliang Xu, PhD - Associate Director of Business Development, PepLib
Peptides - R&D 09:30 - 10:00
Development of novel modality peptide drug: tissue regeneration-inducing medicine
- Katsuto Tamai, M.D, PhD - CSO and Director of StemRIM Inc. and Guest Professor, Osaka University Graduate School of Medicine